Our results are similar to the previously published studies [9, 21, 22]; serum PIVKA-II was obviously superior to AFP for HCC screening and provides further evidence that “AFP + PIVKA-II” was an effective blood-based biomarker facilitating diagnoses of HCC. The gene discussed is AFP; the disease is hepatocellular carcinoma.